Post-Authorisation Safety Study of Esbriet (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting
Latest Information Update: 05 Jul 2023
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms PASSPORT
- Sponsors Roche
- 30 Jun 2023 Results of pooled analysis (from studies ASCEND (NCT01366209), CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), RECAP (NCT00662038), PASSPORT (NCT02699879), and SP-IPF (NCT02951429)published in the Advances in Therapy
- 12 Sep 2017 Data from this trial was presented at the European Respiratory Society (ERS) congress, according to Roche media release.
- 12 Sep 2017 Results published in the Roche Media Release